Home HealthTopics Health Centers Reference Library Search NetWellnessSearch   Advanced
Print this pageEMail this page

Arthritis and Rheumatism

Rheumatoid Arthritis

Rheumatoid Arthritis (RA) is a systemic autoimmune disease that primarily causes joint inflammation. Approximately 1% of the North American population, at any given time, is affected by the disease.1 RA can occur at any age, but is commonly seen in people between 40 and 70.2

What happens to the body

The inflammation of RA may cause changes of joints and surrounding anatomy. These changes may include proliferation of the joint lining (synovial membrane) or structural damage to cartilage, bone, and ligaments. The severity of RA is variable, ranging from self-limited to mild, chronic activity to severe, destructive arthritis. While the joint inflammation may certainly cause the symptom of pain, the destructive potential of the disease can also lead to joint deformity, joint dysfunction, and functional decline of an individual.

Classification of RA

The most widely used tool for classifying RA is the American College of Rheumatology (formerly the American Rheumatism Association) 1987 revised criteria for the classification of rheumatoid arthritis. Listed below are some common clinical characteristics of RA used by the classification criteria:

Treatment

There are three goals for the treatment of RA:

Current therapies available do not allow for a cure of the disease; however, medications may helpful in obtaining one or more goals of treatment. Medications that help slow or halt the progression of joint damage are considered Disease Modifying Anti-Rheumatic Drugs (DMARD's). Medications may be used alone or in combination in order an attempt to reach the desired goals. Below is a table of some, but not all, medications used for the treatment of RA.

Medicine/Class Symptom Relief Disease Modifying
Non-Steroidal Anti-inflammatory (NSAID) i.e., Ibuprofen Naproxen Diclofenac Celecoxib

Yes

No

Corticosteroid (Prednisone Medrol)

Yes

?*

Tetracyline derivative Doxycycline Minocycline

Yes

?*

Hydroxychloroquine (Plaquenil)

Yes

Yes

Sulfasalazine (Azulfidine)

Yes

Yes

Methotrexate (Rheumatrex, Trexall)

Yes

Yes

Leflunomide (Arava)

Yes

Yes

Anakinra (Kineret)

Yes

Yes

Etanercept (Enbrel)

Yes

Yes

Infliximab (Remicade)

Yes

Yes

Adalimumab (Humira)

Yes

Yes

Abatacept (Orencia)

Yes

Yes

Rituximab (Rituxan)

Yes

Likely

Golimumab (Simponi)

 Yes

 ?*

Certolizumab (Cimzia)

 Yes

 ?*


*Disease modifying potential is debated amongst experts. There is known data, but its significance is contentious.

Assessing Disease Activity

Your health care provider may use a number of tools or questions to assess your response to medications prescribed for the treatment of RA. Your provider may assess the number of tender and/or swollen joints that you have in comparison to previous visits. They may ask you the time it takes to reach maximal improvement of your morning stiffness awakening. X-rays may be taken over specific intervals to assess for progression or lack of progression of RA-induced joint damage.

In advance of your appointment, the office may request that you complete a health assessment survey gauging your symptoms and functions. One such survey is the Health Assessment Questionnaire developed at the Stanford University School of Medicine. This survey can be printed, completed and taken to your health care provider.

References

1. Gabriel SE, Crowson, O'Fallon WM. The epidemiology of rheumatoid arthritis in Rochester, MN. Arthritis Rheum 1999;42:415-20.

2. Symmons DPM, Barrett EM, Bankhead CR, et al. The incidence of rheumatoid arthritis in the United Kingdom: Results from the Norfolk Arthritis Register. Br J Rheumatol 1994;33:735-9.

More articles about Arthritis and Rheumatism:

For more information:

Go to the Arthritis and Rheumatism health topic, where you can:

This article is a NetWellness exclusive. NetWellness Article

Last Reviewed: Jun 11, 2009

Case Western Reserve University Raymond Hong, MD, MBA, FACR
Assistant Professor
Division of Rheumatology
University Hospitals
School of Medicine
Case Western Reserve University
Raymond  Hong, MD, MBA, FACR